Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

196440 Batimastat - CAS 130370-60-4 - Calbiochem

196440
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Empirical FormulaCAS #
C₂₃H₃₁N₃O₄S₂130370-60-4

Products

Catalogue NumberPackaging Qty/Pack
196440-5MG Glass bottle 5 mg
Description
OverviewA Marimastat (Cat. No. 444289) type of peptidyl hydroxamate-based inhibitor that potently inhibits a broad-spectrum of metalloproteinases, including MMP-1, MMP-2, MMP-3/stromelysin, MMP-7/matrilysin, MMP-9, ΔMT1 (MMP-14 without TM domain), ADAM8, and ADAM17/TACE (IC50 = 3, 4, 20, 6, 4, 2.08, 51.3, and 19 nM, respectively), by targeting both the substrate binding site and the active-site Zn2+, while being much less potent toward ACE (Angiotensin Converting Enzyme) or α-secretase (IC50 = 1.6 and 3.3 µM, respectively). Batimastat is widely used in studying the involvement of MMPs in cancinogenesis and non-cancer pathological processes both in cultures in vitro and in animals in vivo. Also available as a 25 mM solution in DMSO (Cat. No. 508408).
Catalogue Number196440
Brand Family Calbiochem®
Synonyms(4-N-Hydroxyamino)-2R-isobutyl-3S-(thienylthiomethyl)succinyl)-L-phenylalanine-N-methylamide, BB-94
References
ReferencesSchlomann, U., et al. 2002. J. Biol. Chem. 277, 48210.
Whittaker, M., et al. 1999. Chem. Rev. 99, 2735.
Parvathy, S., et al. 1998. Biochemistry 37, 1680.
Parvathy, S., et al. 1998. FEBS Lett. 431, 63.
Yamamoto, M., et al. 1998. J. Med. Chem. 41, 1209.
Moss, M.L., et al. 1997. Nature 385, 733.
Eccles, S.A., et al. 1996. Cancer Res. 56, 2815.
Brown, P.D. 1995. Advan. Enzyme Regul. 35, 293.
Wang, X., et al. 1994. Cancer Res. 54, 4726.
Davies, B., et al. 1993. Cancer Res. 53, 2087.
Product Information
CAS number130370-60-4
FormOff-white solid
Hill FormulaC₂₃H₃₁N₃O₄S₂
Chemical formulaC₂₃H₃₁N₃O₄S₂
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
ApplicationBatimastat, CAS 130370-60-4, is a potent inhibitor of a several metalloproteinases, including MMP-1, 2, 3, 7, 9, ΔMT1, ADAM8 & ADAM17/TACE (IC50 = 3, 4, 20, 6, 4, 2.08, 51.3 & 19 nM, respectively).
Biological Information
Purity≥98% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

Batimastat - CAS 130370-60-4 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

Batimastat - CAS 130370-60-4 - Calbiochem Certificates of Analysis

TitleLot Number
196440

References

Reference overview
Schlomann, U., et al. 2002. J. Biol. Chem. 277, 48210.
Whittaker, M., et al. 1999. Chem. Rev. 99, 2735.
Parvathy, S., et al. 1998. Biochemistry 37, 1680.
Parvathy, S., et al. 1998. FEBS Lett. 431, 63.
Yamamoto, M., et al. 1998. J. Med. Chem. 41, 1209.
Moss, M.L., et al. 1997. Nature 385, 733.
Eccles, S.A., et al. 1996. Cancer Res. 56, 2815.
Brown, P.D. 1995. Advan. Enzyme Regul. 35, 293.
Wang, X., et al. 1994. Cancer Res. 54, 4726.
Davies, B., et al. 1993. Cancer Res. 53, 2087.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision12-August-2010 RFH
Synonyms(4-N-Hydroxyamino)-2R-isobutyl-3S-(thienylthiomethyl)succinyl)-L-phenylalanine-N-methylamide, BB-94
DescriptionA Marimastat (Cat. No. 444289) type of peptidyl hydroxamate-based inhibitor that potently inhibits a broad-spectrum of metalloproteinases, including MMP-1, MMP-2, MMP-3/stromelysin, MMP-7/matrilysin, MMP-9, ΔMT1 (MMP-14 without TM domain), ADAM8, and ADAM17/TACE (IC50 = 3, 4, 20, 6, 4, 2.08, 51.3, and 19 nM, respectively), by targeting both the substrate binding site and the active-site Zn2+, while being much less potent toward ACE (Angiotensin Converting Enzyme) or α-secretase (IC50 = 1.6 and 3.3 µM, respectively). Batimastat is widely used in studying the involvement of MMPs in cancinogenesis and non-cancer pathological processes both in cultures in vitro and in animals in vivo.
FormOff-white solid
Intert gas (Yes/No) Packaged under inert gas
CAS number130370-60-4
Chemical formulaC₂₃H₃₁N₃O₄S₂
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (50 mg/ml)
Storage +2°C to +8°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesSchlomann, U., et al. 2002. J. Biol. Chem. 277, 48210.
Whittaker, M., et al. 1999. Chem. Rev. 99, 2735.
Parvathy, S., et al. 1998. Biochemistry 37, 1680.
Parvathy, S., et al. 1998. FEBS Lett. 431, 63.
Yamamoto, M., et al. 1998. J. Med. Chem. 41, 1209.
Moss, M.L., et al. 1997. Nature 385, 733.
Eccles, S.A., et al. 1996. Cancer Res. 56, 2815.
Brown, P.D. 1995. Advan. Enzyme Regul. 35, 293.
Wang, X., et al. 1994. Cancer Res. 54, 4726.
Davies, B., et al. 1993. Cancer Res. 53, 2087.